Compare Organon & Co. Common Stock (OGN) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Zillow Group Inc Class A — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Zillow Group Inc Class A trades at $29.49 (market cap $6.42B). The key difference: Zillow Group Inc Class A is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Zillow Group Inc Class A for 86 Days on average.
| OGN | ZG | |
|---|---|---|
Market Cap | $3.61B | $6.42B |
Volume | 1,808,049 | 1,301,685 |
Sector | Health | Media |
52-Week High | $13.81 | $74.58 |
52-Week Low | $5.70 | $27.70 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $11.03B | $6.29B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Zillow Group (ZG) trades at $28.85, up 0.56% on the day, amid a bearish technical signal but with improving fundamentals. The company reported a return to profitability in 2025 with net income of $23 million (source: company earnings, 2025), and revenue growth is projected to continue. Recent news highlights AI integration in real estate and shifting housing market dynamics. Analyst consensus is a 'Hold' with a $48.60 price target, suggesting significant potential upside from current levels.
The outlook is cautiously optimistic. The primary opportunity lies in the substantial gap between the current price and the analyst target, coupled with revenue growth and a strategic pivot. Key risks include persistent housing market affordability headwinds, competitive pressures, and the stock's high P/E ratio of 127.3, which demands sustained earnings growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
